Amundi Euro Stoxx Select Dividend30 UCITS ETF Dist (C051.DE)
About this ETF
This ETF's primary objective is to mirror the returns of the EURO STOXX Select Dividend 30 (Net Return) EUR Index with high fidelity, irrespective of market conditions. The fund targets a minimal divergence from the index, typically keeping its tracking error below 1%. Comprehensive details regarding the index methodology are available in the fund's official prospectus or Key Information Document (KID).
Price
Top 10 holdings
| ABN AMRO BANK NV-CVA ABN.AS | 5.17% |
| OMV AG OMV.VI | 4.81% |
| SIGNIFY NV LIGHT.AS | 4.79% |
| ASR NEDERLAND NV ASRNL.AS | 4.46% |
| NN GROUP NV NN.AS | 4.41% |
| POSTE ITALIANE SPA PST.MI | 4.41% |
| RANDSTAD NV RAND.AS | 4.30% |
| AXA SA CS.PA | 3.93% |
| CREDIT AGRICOLE SA ACA.PA | 3.82% |
| BNP PARIBAS BNP.PA | 3.77% |
Sector mix
Price chart
Returns
| 1 month | +1.52% |
| 3 months | +6.36% |
| 6 months | +11.18% |
| Year to date | +11.58% |
| 1 year | +17.34% |
| 3 years (ann.) | +14.76% |
| 5 years (ann.) | +5.33% |
| 10 years (ann.) | +2.84% |
Risk profile
| Volatility (1y, ann.) | 13.17% |
| Sharpe (1y) | 1.28 |
| Sharpe (3y) | 1.05 |
| Sortino (1y) | 1.62 |
| Max drawdown (1y) | -7.46% |
| Max drawdown (5y) | -30.27% |
| Max drawdown (full) | -56.43% |
| Beta vs S&P 500 (1y) | 0.37 |
| Correlation vs S&P 500 (1y) | 0.35 |
Technical outlook as of 2026-07-13
The Monte Carlo cone is drawn on the price chart above (Forecast overlay); RSI, MACD and the rest of the oscillators live in its indicator panels.
Full holdings
| Constituent | ISIN | Market value | Weight |
|---|---|---|---|
| Loading… | |||
Sector breakdown
Geographic exposure
Cost vs. peers
Comparison universe: 6,948 funds of the same asset class.
Cost impact calculator
Dividend history
Distributing share class Income is paid out to shareholders.
| Ex-date | Payment | Amount |
|---|---|---|
| 2025-12-09 | 2025-12-11 | EUR 2.0700 |
| 2024-12-10 | 2024-12-12 | EUR 1.7200 |
| 2023-09-26 | 2023-09-28 | EUR 1.9900 |
| 2022-07-06 | 2022-07-08 | EUR 1.6000 |
| 2021-07-07 | 2021-07-09 | EUR 1.3400 |
| 2020-08-21 | 2020-08-25 | EUR 1.3400 |
| 2019-08-20 | 2019-08-22 | EUR 1.9437 |
| 2018-08-21 | 2018-08-23 | EUR 1.7094 |
| 2017-12-27 | 2017-12-29 | EUR 0.2423 |
| 2017-08-28 | 2017-08-30 | EUR 1.7073 |
ESG profile
No ESG estimate available: none of the scored universe overlaps this portfolio (typical for bond, commodity or synthetic funds).
Scored coverage: 0.0% of the portfolio by weight.
Similar ETFs
| Fund | TER | AUM (USD) | Yield (TTM) | Return 1y | Sharpe 1y |
|---|---|---|---|---|---|
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.05% | +19.93% | 1.48 |
| Vanguard S&P 500 ETF VOO | 0.03% | 1.70T | 1.07% | +19.68% | 1.49 |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 1.09% | +19.68% | 1.49 |
| State Street SPDR S&P 500 ETF SPY | 0.09% | 789.23B | 1.00% | +19.71% | 1.49 |
| SPDR S&P 500 ETF Trust 1557.T | 0.09% | 789.09B | 0.49% | +37.54% | 2.26 |
| State Street SPDR S&P 500 ETF SPY.AX | 0.09% | 788.13B | 1.00% | +11.84% | 1.13 |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.61% | +20.58% | 1.21 |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 0.43% | +28.14% | 1.43 |
| Vanguard Growth ETF VUG | 0.03% | 393.80B | 0.39% | +16.85% | 0.99 |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 2.60% | +21.64% | 1.23 |
Cheaper alternatives
No fund of the class reaches 60% portfolio overlap — showing the cheapest funds of the class instead.
| Fund | TER | AUM (USD) | Overlap |
|---|---|---|---|
| iShares Core MSCI EAFE ETF IEFA | 0.07% | 187.22B | 4.5% |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 3.4% |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.5% |
| iShares Core MSCI World UCITS ETF IWDA.AS | 0.20% | 143.20B | 1.3% |
| iShares Core MSCI World UCITS ETF SWDA.L | 0.20% | 143.31B | 1.3% |

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
